Morgan Stanley analyst Terence Flynn maintains $Johnson & Johnson (JNJ.US)$ with a hold rating, and adjusts the target price from $169 to $175.
According to TipRanks data, the analyst has a success rate of 59.8% and a total average return of 11.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Following a third-quarter report that was broadly in line with projections, including stronger performance in Pharmaceuticals and a slight lag in Medtech, and commentary on 2025 that matched expectations, modest revisions have been made to the estimates.
Following the recent quarterly report, the outlook for Johnson & Johnson has become more favorable with progress in the talc litigation settlement proposal, strategic medical technology acquisitions, and forward-looking commentary for 2025.
Following its Q3 earnings surpassing forecasts, Johnson & Johnson demonstrated a notable 5.6% growth in its core operations, excluding Covid-related impacts, surpassing expectations primarily due to its Innovative Medicine sector, while the MedTech segment experienced a lag, attributed to usual seasonal patterns and challenges in the Asia Pacific region. The company is observed to be making considerable operational advancements, with its focus on executing its pipeline strategy beginning to manifest.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Terence Flynn維持$強生 (JNJ.US)$持有評級，並將目標價從169美元上調至175美元。
根據TipRanks數據顯示，該分析師近一年總勝率為59.8%，總平均回報率為11.1%。
此外，綜合報道，$強生 (JNJ.US)$近期主要分析師觀點如下：
在第三季度報告中，製藥業績較好，醫療技術略顯滯後，2025年的評論符合預期，故對預估做出了適度調整。
隨着最近的季度報告，強生公司的前景變得更加樂觀，石粉訴訟解決方案取得進展，醫療技術戰略收購，以及2025年的展望性評論。
在公佈第三季度盈利超過預期後，強生公司核心業務實現了明顯的5.6%增長，不計入新冠疫情影響，主要得益於創新藥板塊，而醫療技術板塊出現滯後，主要歸因於常規季節性模式和亞太地區的挑戰。公司正在進行重大的運營進展，集中於實施其管道策略，開始顯現成效。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
